

**Cookies**

Our site uses cookies to improve your experience. You can find out more about our use of cookies in [About Cookies](#), including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in [About Cookies](#).

I accept



Cochrane Database of Systematic Reviews | [Protocol - Prognosis](#)

Prognostic value of the androgen receptor in addition to the established hormone receptors and HER2 status for predicting survival in women with early breast cancer

Menaka Dilani S Lokuhetty, Harshima D Wijesinghe, Johanna AAG Damen, Teresa Lee, Valerie A White, Ian A Cree,

Blanca Iciar Indave [Authors' declarations of interest](#)

Version published: 16 November 2020

<https://doi.org/10.1002/14651858.CD013784>

Abstract

Objectives

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:

Primary objectives

The primary objective is to summarise available evidence on the overall prognostic value of androgen receptor (AR) expression, in addition to hormone receptors and HER2 status, for predicting survival in women with early breast cancer.

Secondary objectives

The secondary objectives are to evaluate disease-free survival, breast cancer-specific survival, and metastasis-free survival as prognostic outcomes.

